AKT1 and neoplasm: In detail, PTEN loss was determined via IHC using the absence of PTEN staining in 50% or more of the specimen’s tumor area; NGS to examine PTEN status or PIK3CA/AKT1/PTEN alteration was performed using a FoundationOne CDx NGS assay [93].